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        Abstract
Aim
Lighthouse Trust in Lilongwe, Malawi serves approximately 25,000 patients with HIV antiretroviral therapy (ART) regimens standardized according 
to national treatment guidelines. However, as a referral centre for complex cases, Lighthouse Trust occasionally treats patients with non-standard ART 
regimens (NS-ART) that deviate from the treatment guidelines. We evaluated factors contributing to the use of  NS-ART and whether patients could 
transition to standard regimens.
Methods
This was a cross-sectional study of  all adult patients at Lighthouse Trust being treated with NS-ART as of  February 2012. Patients were identified using 
the electronic data system. Medical charts were reviewed and descriptive statistics were obtained.
Results
One hundred six patients were initially found being treated with NS-ART, and 92 adult patients were confirmed to be on NS-ART after review. Mean 
patient age was 42.4 ± 10.3 years, and 52 (57%) were female. Mean duration of  treatment with the NS-ART being used at the time of  data collection 
was 2.1 ± 1.5 years. Eight patients (9%) were on modified first-line NS-ART and 84 (91%) were on modified second-line NS-ART, with 90 patients 
(98%) having multiple factors contributing to NS-ART use. Severe toxicity from one medication contributed in 28 cases (30%) and toxicity from 
multiple medications contributed in 46 cases (50%), while 22 patients (24%) were transitioned to NS-ART following a stockout of  their original 
medication. Following clinical review, 84 patients (91%) were transitioned to standard regimens, and eight (9%) were maintained on NS-ART because 
of  incompatibility of  their clinical features with the latest national guidelines.
Conclusions 
Primary factors contributing to NS-ART use were medication toxicities and medication stockouts. Most patients were transitioned to standard regimens, 
although the need for NS-ART remains. 
Introduction
Free antiretroviral therapy (ART) for individuals living with 
HIV was introduced in Malawi in 2004, with nearly 400,000 
patients being treated as of  September 2012.1 ART guidelines 
have been standardized since programme inception, with 
common first- and second-line regimens across the country. 
Despite these guidelines, a small number of  patients 
throughout the country are treated with non-standard ART 
regimens (NS-ART).
Lighthouse Trust, in Malawi’s capital of  Lilongwe, serves 
approximately 25,000 patients living with HIV by providing 
the aforementioned standardized ART regimens at two 
clinics. As a referral centre for complex cases, Lighthouse 
Trust occasionally treats patients with NS-ART. The use of  
such regimens is largely managed on a case-by-case basis, and 
there is a lack of  synthesized data related to the underlying 
reasons for using NS-ART. Challenges in quantifying these 
regimens have resulted in medication stockouts in the past, 
necessitating further modifications. 
The aim of  this study was to evaluate the use of  NS-ART 
at Lighthouse Trust in order to determine the reasons for 
the use of  NS-ART and assess whether patients could safely 
transition to standard ART regimens following the 2011 
national HIV treatment guideline change in Malawi.
Methods
Study design and population
We conducted a cross-sectional study of  routinely gathered 
data at Lighthouse Trust’s two public ART clinics in  Lilongwe, 
Malawi: (1) Lighthouse Clinic and (2) Martin Preuss Centre 
(MPC). This study included all patients 18 years of  age and 
older at Lighthouse Trust who were being treated with NS-
ART as of  February 2012. ART regimens in the country 
are standardized according to national treatment guidelines. 
Prior to 2011, ART regimens in Malawi were dictated by the 
Guidelines for the Use of  Antiretroviral Therapy in Malawi, 
3rd Edition.2 According to these guidelines, the first-line 
treatment regimen was with lamivudine, nevirapine, and 
stavudine, in the form of  the fixed-medication combination 
Triomune. In cases of  nevirapine-associated toxicity, 
efavirenz could be substituted, and in cases of  toxicity 
attributed to stavudine, zidovudine could be substituted. In 
cases of  dual reactions to stavudine and nevirapine, patients 
were switched to a regimen of  zidovudine, lamivudine, and 
efavirenz. In cases of  first-line regimen treatment failure, 
second-line therapy consisted of  zidovudine, lamivudine, 
tenofovir and lopinavir/ritonavir.
A more recent set of  Malawian national guidelines 
was implemented in July 2011, with first-line ART also 
consisting of  lamivudine, nevirapine, and stavudine in the 
form of  Triomune.3 In cases of  toxicity, zidovudine or 
tenofovir could be substituted for stavudine (in cases of  
severe peripheral neuropathy, pancreatitis, lactic acidosis, 
or lypodystrophy), and efavirenz for nevirapine (in cases of  
severe skin reactions or hepatitis). For breastfeeding women, 
pregnant women, and TB/HIV co-infected patients, 
efavirenz, lamivudine, and tenofovir became available for 
first-line therapy. In cases of  dual reactions to stavudine and 
nevirapine, patients were switched to a regimen of  efavirenz, 
lamivudine, and zidovudine. However, individual lamivudine 
was not available (as it had been prior to 2011). Patients 
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failing first-line ART were transitioned to second-line ART, 
which included lopinavir/ritonavir and either tenofovir or 
zidovudine combined with lamivudine. 
Data collection
All patients who receive care at Lighthouse and MPC for 
treatment of  HIV are registered in the clinics’ electronic 
data system (EDS). As directed by the national treatment 
guidelines in place during the study period, all adults who 
were HIV-seropositive were initiated on ART if  they had a 
CD4-lymphocyte count ≤ 350 cells/mm3 or were assessed 
to be in WHO clinical stages III or IV. Using EDS data, 
we retrospectively identified 106 patients as being treated 
with NS-ART as of  February 28, 2012 and subsequently 
performed chart reviews. Data about patient demographics, 
treatments, and reasons for alterations in treatment were 
extracted and managed using REDCap electronic data 
capture tools.4
Statistical analysis
Descriptive statistics were used to describe the characteristics 
of  the study population and were obtained using Stata® 
version 11.0 (Stata Corporation, College Station, Texas, 
USA).
Ethical considerations
The study proposal was approved by the Malawi National 
Health Sciences Research Committee and the School of  
Medicine Institutional Review Board at the University of  
North Carolina at Chapel Hill. Additionally, all records used 
in this study were de-identified prior to being analysed.
Results
Of  the 17,000 patients being treated at Lighthouse Trust for 
HIV in February 2012, 106 were identified in the EDS as 
being treated with NS-ART, and their files were reviewed. 
Upon further investigation, it was noted that 12 cases were 
mistakenly identified as using NS-ART, leaving 94 confirmed 
patients being treated with NS-ART. Two patients were 
excluded because they were less than 18 years of  age, leaving 
92 patients eligible for this study (Table 1). 
Table 1: Patient demographic and clinical characteristics
Mean patient age was 42.4 ± 10.3 years and 52 patients (57%) 
were female. Fifty-nine patients (64%) had been initiated on 
ART after being designated as having WHO clinical stage III 
disease, while eight (9%) had WHO clinical stage IV disease, 
and 25 (27%) had either WHO clinical stage I or II disease 
with a CD4-lymphocyte count ≤ 350 cells/mm3.
Patients were being treated with twenty different non-
standard combinations of  ART, and these regimens were 
usually the third ART regimens used during the course of  
their HIV management. The most common NS-ARTs used 
are listed in Table 2. 
Table 2: Most common non-standard antiretroviral therapy regimens
The most common contributing factor for being transitioned 
to NS-ART was severe toxicity from multiple antiretroviral 
(ARV) medications, which affected 46 patients (50%). 
Additional contributory factors are detailed in Table 3. 
Table 3: Reasons for patients being managed with non-standard 
antiretroviral therapy regimens
The medications most likely to induce toxicities contributing 
to NS-ART use were stavudine (35 patients, 38%), nevirapine 
(29 patients, 32%), efavirenz (26 patients, 28%), zidovudine 
(21 patients, 23%), and tenofovir (13 patients, 14%). Nearly 
all patients (n = 90; 98%) had multiple contributing factors 
for eventually being switched to treatment with NS-ART.
Following chart review, 84 patients (91%) were transitioned 
to a standard ART regimen according to the 2011 guidelines, 
and eight (9%) were maintained on NS-ART.  Of  those 
who were maintained on NS-ART, three (37.5%) were 
on a modified second-line NS-ART because of  toxicity 
attributed to lopinavir/ritonavir, while the other five (62.5%) 
demonstrated toxicity associated with all or all but one of  
the standard nucleoside reverse transcriptase inhibitors 
(NRTIs), which include lamivudine, stavudine, zidovudine, 
and tenofovir. Notably, none of  the patients in the latter 
group had ever been treated with abacavir, which is also an 
NRTI, but was only included in 2011 Malawian treatment 
guidelines for children and not adults.
Discussion 
Less than 1% of  the 17,000 patients receiving ART for 
treatment of  HIV at Lighthouse Trust in 2012 were being 
treated with NS-ART, signifying a strong adherence to 
standardized regimens by clinicians. Assessing the reasons 
for use of  NS-ART is essential to ensuring that optimal 
patient care is provided and that the clinics’ adherence to 
national guidelines remains high. The use of  NS-ART at 
Lighthouse Trust is multifactorial in origin, with clinic-level 
factors, limitations of  national guidelines for individualized 
 
Patient demographic and clinical characteristics (N = 92) 
 mean ± SD 
Age (years) 42.4 ± 10.3  
CD4 count at initiation (cells/mm3 ) 213 ± 116 
Duration of ART (years) 5.6 ± 3.4  
Duration of treatment on any NS-ART (years) 2.2 ± 1.5  
Duration of treatment on current NS-ART (years) 2.1 ± 1.5  
 n (%) 
Female gender 52 (57) 
WHO Stage III 59 (64) 
WHO Stage IV 8 (9) 
CD4 count ≤ 350 cells/mm3 25 (27) 
Being treated with first-line NS-ART 8 (9) 
Being treated with modified second-line NS-ART 84 (91)  
SD = standard deviation; ART = antiretroviral therapy; 
NS-ART = non-standard ART regimen 
Regimen n (%) 
lopinavir/ritonavir monotherapy  30 (33) 
stavudine + lamivudine + lopinavir/ritonavir  21 (23) 
zidovudine + lamivudine + tenofovir + lopinavir/ritonavir* 11 (12) 
lopinavir/ritonavir + tenofovir 5 (5) 
Other  27 (29) 
*Regimen was standard in 2008 guidelines but did not conform to 2011 guidelines 
Reason n (%)* 
Severe toxicity from multiple antiretroviral medications 46 (50) 
Severe toxicity from one antiretroviral medication 28 (30) 
Medication stockout while on standard regimen 22 (24) 
Transferred in from an antiretroviral therapy study 22 (24) 
Treatment according to previous guidelines 12 (13) 
Pregnancy 6 (7) 
Other  5 (5) 
*Percentages total greater than 100 because most patients were on non-standard 
regimens for more than of these reasons 
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line therapy, the use of  raltegravir with lopinavir/ritonavir, 
an NRTI-sparing regimen, is effective and may provide 
treatment options for those unable to tolerate NRTIs.8,9 
The maintenance of  ART for those requiring individualized 
treatment poses a challenge for the HIV programme. This 
potential stumbling block likely can be managed by the use 
of  specialized ordering through centres of  excellence given 
the relatively small scope at present.
In summary, our analysis underscores the need to critically 
evaluate existing patients’ ART regimens as guidelines 
change to ensure they have access to sustainable, effective 
ART and to support the use of  Malawi’s standardized ART 
treatment guidelines.
Table 4: A comparison of antiretroviral (ARV) medication formulations 
available in Malawi in years when national guidelines were updated
regimens, and medication supply ordering challenges 
being major contributors. Overall, use of  NS-ART did not 
suggest suboptimal care but rather limitations of  the current 
repertoire of  ARV medications, which leads to difficulties 
managing patients with medication toxicities.  
The contribution of  medication shortages illustrates the 
impact of  uncertainty in Malawi’s ART supply chain. Malawi 
has struggled with national medication stockouts in the past, 
especially as the number of  different ART regimens in use 
has increased,5 despite the expectation that expansion of  
available regimens would reduce the percentage of  patients 
needing treatment with NS-ART because of  medication 
toxicities. Though stockouts are uncommon for medications 
that are part of  standardized regimens, challenges remain 
with predicting the necessary quantities of  non-standard 
medications being used, and this uncertainty often leads to 
further alterations of  NS-ARTs. Prior to regular access to 
tenofovir/lamivudine as a fixed-dose combination within the 
programme, individual supplies of  tenofovir, lamivudine, and 
the non-nucleoside reverse transcriptase inhibitor (NNRTI) 
were required for tenofovir to be used when faced with 
stavudine and zidovudine toxicity. Any breach in the supply 
chain to the individual components could lead to potentially 
suboptimal regimens being provided as an interim solution 
in response to a short-term medication stockout. At the 
clinic level, one point of  intervention would be to regularly 
review the medication regimens for each patient at every visit 
to ensure that an NS-ART that may have initiated because 
of  a stockout is no longer continued after the stockout has 
resolved.
Though most patients had multiple reasons for treatment 
with NS-ART, most of  them could still be transitioned to 
standard regimens after review. Given the small number of  
patients (92) in our clinics being treated with NS-ART at the 
time of  this investigation, our study is limited by its small 
sample size, as well as its retrospective nature, which may 
have led to the omission of  some factors contributing to 
the use of  NS-ART. Still, the need for NS-ART remains in 
some of  the cases reviewed here, suggesting a potential role 
for additional medications for toxicity management, such as 
abacavir in adults, or an alternative to lopinavir/ritonavir, or 
the addition of  the integrase inhibitor class of  drugs.  Notably, 
the 2014 Malawi guidelines address many of  the shortfalls 
noted in the 2008 and 2011 guidelines: abacavir/lamivudine 
has been added as an NRTI backbone for both adults and 
children, and atazanavir/ritonavir has become the protease 
inhibitor combination of  choice for second-line treatment, 
with lopinavir/ritonavir now serving as an alternative.6 This 
is particularly important since nearly half  of  patients being 
treated with NS-ART were on second-line therapy. With only 
one standard second-line treatment regimen available prior 
to 2014, any additional medication toxicity resulted in the use 
of  NS-ART, either by discontinuation of  the problematic 
drug or by its replacement.
Table 4 compares the ARV medication formulations 
available in Malawi in 2008, 2011, and 2014.2,3,6 In addition 
to combination formulations, previously there were also 
single medication formulations available for use in NS-
ARTs. A remaining shortfall of  the current 2014 guidelines 
exists in the extremely rare situation of  lamivudine toxicity, 
most commonly manifested as red cell aplasia,7 or in patients 
with renal failure, for whom NRTI dose reductions may 
not be possible with fixed-dose combinations. In second-
Case 1
A 60-year-old male, who was diagnosed with HIV in June 
2005 and had a baseline CD4 count of  138 cells/mm3, 
serves as the first example. He initiated ART with a fixed-
dose combination of  lamivudine, nevirapine, and stavudine. 
He developed hepatitis secondary to nevirapine, which was 
replaced with efavirenz in January 2010, while maintaining the 
stavudine and lamivudine. A few months later, in May 2010, 
he developed depression, confusion, and insomnia. This was 
suspected to be caused by efavirenz, which was replaced with 
lopinavir/ritonavir. Unfortunately, he was not able to tolerate 
this change because of  the resulting gastrointestinal upset. 
Around this time, he also developed peripheral neuropathy 
believed to be secondary to stavudine. Finally, in September 
2010, his regimen was changed to lamivudine, tenofovir, 
and zidovudine (a three-NRTI combination) because of  the 
lack of  alternatives to lopinavir/ritonavir. For ART-naïve 
patients, three-NRTI regimens can maintain HIV-RNA 
suppression,10,11 although not as efficaciously as regimens 
containing two NRTIs and an NNRTI. After our study this 
ARV medication formulation 2008 2011 2014 
abacavir P   
abacavir/lamivudine  P X 
atazanavir/ritonavir   X* 
didanosine P   
efavirenz X X X 
efavirenz/lamivudine/tenofovir  X X 
lamivudine X   
lamivudine/nevirapine/stavudine  X X X 
lamivudine/nevirapine/zidovudine  X X 
lamivudine/stavudine  X X X 
lamivudine/tenofovir  X X 
lamivudine/zidovudine  X X X 
lopinavir/ritonavir X X P** 
nevirapine X X X 
tenofovir X   
“X” indicates that a formulation was available in Malawi, while “P” 
indicates a medication that was available, but only for use in paediatric 
patients. 
 
*The atazanavir/ritonavir formulation became available in Malawi in April 
2013, prior to the release of the 2014 guidelines. 
 
**Lopinavir/ritonavir is also available for treatment of adults with HIV 
and tuberculosis during simultaneous antiretroviral and rifampicin-based 
antituberculosis treatment. 
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patient was initially maintained on this regimen. He could 
only be transitioned to a standard regimen when atazanavir/
ritonavir became available to the ART programme in April 
2013. He thereafter was managed on atazanavir/ritonavir, 
lamivudine, and tenofovir.  
Case 2.
The second example is a female patient who was 50 years 
old during the study period. She was diagnosed with HIV 
(WHO stage III) in February 2005. ART was initiated with 
lamivudine, nevirapine, and stavudine. In October 2006 
stavudine was replaced with zidovudine after she experienced 
peripheral neuropathy. However, in September 2008 the 
patient’s zidovudine was replaced with abacavir because she 
developed anaemia. Thereafter, the patient’s abacavir was 
discontinued after she experienced severe GI intolerance 
(presumed to be hypersensitivity) and her regimen was 
changed to lopinavir/ritonavir, lamivudine, and tenofovir. 
However, in February 2010 the patient developed renal 
failure secondary to tenofovir and was placed on lopinavir/
ritonavir monotherapy. She was maintained on this after 
review. Monotherapy regimens have been shown to effect 
reasonable virologic suppression and clinical outcomes, 
although a combination of  a protease inhibitor and integrase 
inhibitor would be preferred in such an individual with 
multiple NRTI toxicities8,12,13.
Case 3.
The final example is a female patient who was 44 years 
old during data collection. She was diagnosed with HIV 
in March 2009. Her initial CD4 count was 236 cells/
mm3. ART was initiated with lamivudine, nevirapine, and 
stavudine. She experienced a rash, attributed to nevirapine, 
after which nevirapine was replaced with efavirenz in May 
2009. However, in the following months she developed 
confusion, which was attributed to efavirenz. In August 2009 
efavirenz was discontinued and replaced with lopinavir/
ritonavir. After review, the patient’s non-standard regimen 
(lamivudine, lopinavir/ritonavir, and stavudine) was changed 
to a standardized regimen of  lopinavir/ritonavir, lamivudine, 
and tenofovir. 
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